CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Eterna Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Eterna Therapeutics Inc
1035 Cambridge Street, Suite 18A
Phone: (212) 582-1199p:212 582-1199 CAMBRIDGE, MA  02141  United States Ticker: ERNAERNA

Business Summary
Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202412/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board JamesBristol 12/19/2023 10/30/2023
President, Chief Executive Officer SanjeevLuther 62 1/1/2024 1/1/2024
Chief Financial Officer SandraGurrola 56 5/4/2023 9/8/2014
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Novellus Therapeutics Limited 7-8 Wilton Terrace Dublin 2 United Kingdom

Business Names
Business Name
Brooklyn ImmunoTherapeutics, Inc.
BTX
ERNA
5 additional Business Names available in full report.

General Information
Number of Employees: 8 (As of 3/12/2024)
Outstanding Shares: 5,410,331 (As of 5/13/2024)
Shareholders: 155
Stock Exchange: NASD
Federal Tax Id: 311103425
Fax Number: (302) 655-5049
Email Address: investor@ntn.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 19, 2024